| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Grunden JW and Fisher KA | Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220046 |
| Mikasa K et al. | Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. | 1997 Jul-Aug | Chemotherapy | pmid:9209786 |
| Nawarskas JJ et al. | Digoxin toxicity secondary to clarithromycin therapy. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220047 |
| al-Humayyd MS | Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. | 1997 Mar-Apr | Chemotherapy | pmid:9084915 |
| Svoboda P et al. | Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. | 1997 May-Jun | Hepatogastroenterology | pmid:9222709 |
| Best LM et al. | Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218854 |
| O'Brien B et al. | Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218858 |
| Guerriero SE et al. | Two cases of clarithromycin-induced digoxin toxicity. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324195 |
| Anzueto A et al. | Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. | 1997 Sep-Oct | Clin Ther | pmid:9385486 |
| Al-Sibai MB et al. | Ocular penetration of oral clarithromycin in humans. | 1998 | J Ocul Pharmacol Ther | pmid:9867340 |
| Wallace RJ and Brown BA | Catheter sepsis due to Mycobacterium chelonae. | 1998 | J. Clin. Microbiol. | pmid:9867491 |
| Shafran SD et al. | Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group. | 1998 | Clin. Infect. Dis. | pmid:9868650 |
| van Westrhenen R et al. | Pneumonia and glomerulonephritis caused by Mycoplasma pneumoniae. | 1998 | Nephrol. Dial. Transplant. | pmid:9870493 |
| Waddell ST et al. | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9871759 |
| Lee CL et al. | One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. | 1998 | J. Formos. Med. Assoc. | pmid:9872028 |
| Abouesh A and Hobbs WR | Clarithromycin-induced mania. | 1998 | Am J Psychiatry | pmid:9812131 |
| Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
| Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9756789 |
| Sackoff J et al. | Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. | 1998 | J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. | pmid:9833748 |
| Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
| Debets-Ossenkopp YJ et al. | Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9756790 |
| Mukunda BN et al. | Clarithromycin therapy for bacillary peliosis did not prevent bacillary angiomatosis. | 1998 | Clin. Infect. Dis. | pmid:9770180 |
| Hogan PA and Sheehan DJ | Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. | 1998 | Antimicrob. Agents Chemother. | pmid:9835536 |
| Stack WA et al. | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. | 1998 | Am. J. Gastroenterol. | pmid:9772054 |
| Adamek RJ and Bethke TD | Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. | 1998 | Am. J. Gastroenterol. | pmid:9772056 |
| Stolte M et al. | Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. | 1998 | Z Gastroenterol | pmid:9773482 |
| Hawkey CJ et al. | Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. | 1998 | Lancet | pmid:9759744 |
| Mégraud F and Doermann HP | Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. | 1998 | Gut | pmid:9764043 |
| Heald AE et al. | Taste and smell complaints in HIV-infected patients. | 1998 | AIDS | pmid:9764787 |
| Perri F et al. | Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. | 1998 | Ital J Gastroenterol Hepatol | pmid:9675647 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Lygren I et al. | [Treatment of Helicobacter pylori infection]. | 1998 | Tidsskr. Nor. Laegeforen. | pmid:9889634 |
| Einarson A et al. | A prospective controlled multicentre study of clarithromycin in pregnancy. | 1998 | Am J Perinatol | pmid:9890248 |
| Abe M et al. | A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. | 1998 | Respir Med | pmid:9893782 |
| Warheker PT et al. | Successful treatment of saccular endophthalmitis with clarithromycin. | 1998 | Eye (Lond) | pmid:10326009 |
| Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
| Bocheńska-Marciniak M et al. | [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. | 1998 | Pol. Arch. Med. Wewn. | pmid:10335027 |
| Griffith DE | Mycobacteria as pathogens of respiratory infection. | 1998 | Infect. Dis. Clin. North Am. | pmid:9779380 |
| Casswall TH et al. | One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. | 1998 | J. Pediatr. Gastroenterol. Nutr. | pmid:9779970 |
| Aberg JA et al. | Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. | 1998 | J. Infect. Dis. | pmid:9780266 |
| González Carro P et al. | [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. | 1998 | Rev Esp Enferm Dig | pmid:9780793 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Gangadharam PR | Clarithromycin for non-mycobacterial diseases? | 1998 | Int. J. Tuberc. Lung Dis. | pmid:9783536 |
| Shafran SD et al. | Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. | 1998 | J. Infect. Dis. | pmid:9419201 |
| Butt AA | Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. | 1998 | Am. J. Med. Sci. | pmid:9427575 |
| van Aarem A et al. | Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. | 1998 | Int. J. Pediatr. Otorhinolaryngol. | pmid:9596371 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
| Jarboe E et al. | Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9572027 |
| Treiber G et al. | Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. | 1998 | Helicobacter | pmid:9546119 |
| Suzuki J et al. | Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. | 1998 | Helicobacter | pmid:9546120 |
| Lindsetmo RO et al. | Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. | 1998 | Scand. J. Gastroenterol. | pmid:9548613 |
| Comet R et al. | [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. | 1998 | Gastroenterol Hepatol | pmid:9549183 |
| Carnicer J | [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. | 1998 | Gastroenterol Hepatol | pmid:9549199 |
| Iwata M et al. | [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9549331 |
| Champney WS and Burdine R | Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. | 1998 | Microb. Drug Resist. | pmid:9818968 |
| Murata H et al. | Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. | 1998 | Am. J. Gastroenterol. | pmid:9820380 |
| Laine L et al. | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. | 1998 | Am. J. Gastroenterol. | pmid:9820381 |
| Kaeser YA et al. | Severe hypotension and bradycardia associated with verapamil and clarithromycin. | 1998 | Am J Health Syst Pharm | pmid:9825040 |
| Hua J et al. | Characterization of clinical isolates of Helicobacter pylori in Singapore. | 1998 | Microbios | pmid:9785486 |
| Clark CL et al. | Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies. | 1998 | J. Clin. Microbiol. | pmid:9817876 |
| Yano S et al. | [Significance of therapeutic efficacy of clarithromycin in a model for human lung cancer metastasis and a mouse tumor system]. | 1998 | Jpn J Antibiot | pmid:9597491 |
| Björkholm B et al. | Rapid PCR detection of Helicobacter pylori-associated virulence and resistance genes directly from gastric biopsy material. | 1998 | J. Clin. Microbiol. | pmid:9817898 |
| Sasa K et al. | [Antineoplastic therapeutic effect of clarithromycin in rats]. | 1998 | Jpn J Antibiot | pmid:9597492 |
| Arimori K et al. | Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. | 1998 | Biopharm Drug Dispos | pmid:9818709 |
| Cirioni O et al. | In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. | 1998 | J. Antimicrob. Chemother. | pmid:9818742 |
| Miyamoto N et al. | [Test to set dosages for long-term administration of clarithromycin to treat chronic paranasal sinusitis]. | 1998 | Jpn J Antibiot | pmid:9597498 |
| Fujita K et al. | [Neutrophil count and IL-8 level of nasal secretion of patients with chronic paranasal sinusitis and the effects of macrolide antibiotics]. | 1998 | Jpn J Antibiot | pmid:9597505 |
| Pontani D et al. | Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. | 1998 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:9758284 |
| Scheen AJ | [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. | 1998 | Rev Med Liege | pmid:9555183 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Goujard C et al. | Clarithromycin-resistant Mycobacterium avium strain in a clarithromycin-naive AIDS patient. | 1998 | Clin. Infect. Dis. | pmid:9455532 |
| Williamson R et al. | New options in Helicobacter pylori eradication: efficacy, resistance and synergy. | 1998 | Scand. J. Gastroenterol. Suppl. | pmid:9515751 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
| Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
| Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |
| Laine L and Fendrick AM | Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. | 1998 | Postgrad Med | pmid:9519040 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Lacy MK et al. | Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. | 1998 | Int. J. Antimicrob. Agents | pmid:9916901 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Fera MT et al. | Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. | 1998 | Int. J. Antimicrob. Agents | pmid:9916902 |
| Roussel G and Igual J | Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. | 1998 | Int. J. Tuberc. Lung Dis. | pmid:9626603 |
| Archimandritis A et al. | Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. | 1998 | J. Intern. Med. | pmid:9627163 |
| Petersen AM et al. | [Resistance of Helicobacter pylori to clarithomycin]. | 1998 | Ugeskr. Laeg. | pmid:9627511 |
| Domingo D et al. | High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. | 1998 | J. Antimicrob. Chemother. | pmid:9630414 |
| Fireman Z et al. | Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel. | 1998 | Helicobacter | pmid:9631306 |
| Battaglia G et al. | Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. | 1998 | Helicobacter | pmid:9631310 |
| Ward TT et al. | Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. | 1998 | Clin. Infect. Dis. | pmid:9827282 |
| Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
| Burman WJ et al. | AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9635911 |
| Nordt SP et al. | Clarithromycin induced digoxin toxicity. | 1998 | J Accid Emerg Med | pmid:9639187 |
| Gray VS | Syncopal episodes associated with cisapride and concurrent drugs. | 1998 | Ann Pharmacother | pmid:9640482 |
| Grove DI et al. | Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. | 1998 | Pathology | pmid:9643503 |
| Greenblatt DJ et al. | Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. | 1998 | Clin. Pharmacol. Ther. | pmid:9757151 |
| Makhani S et al. | Atypical cervico-facial mycobacterial infections in childhood. | 1998 | Br J Oral Maxillofac Surg | pmid:9643597 |
| Piccolomini R et al. | Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. | 1998 | Antimicrob. Agents Chemother. | pmid:9797240 |